-+ 0.00%
-+ 0.00%
-+ 0.00%

Q3 earnings review: Outpatient & specialty care stocks led by LifeStance Health Group

Barchart·11/20/2026 08:42:12
Listen to the news

LFST Cover Image

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the outpatient & specialty care industry, including LifeStance Health Group NASDAQ:LFST and its peers.

The outpatient and specialty care industry delivers targeted medical services in non-hospital settings that are often cost-effective compared to inpatient alternatives. This means that they are more desired as rising healthcare costs and ways to combat them become more and more top-of-mind. Outpatient and specialty care providers boast revenue streams that are stable due to the recurring nature of treatment for chronic conditions and long-term patient relationships. However, their reliance on government reimbursement programs like Medicare means stroke-of-the-pen risk. Additionally, scaling a network of facilities can be capital-intensive with uneven return profiles amid competition from integrated healthcare systems. Looking ahead, the industry is positioned to grow as demand for outpatient services expands, driven by aging populations, a rising prevalence of chronic diseases, and a shift toward value-based care models. Tailwinds include advancements in medical technology that support more complex procedures in outpatient settings and the increasing focus on preventive care, which can be aided by data and AI. However, headwinds such as reimbursement rate cuts, labor shortages, and the financial strain of digitization may temper growth.

The 5 outpatient & specialty care stocks we track reported a favorable Q3. As a group, revenues beat analysts’ consensus estimates by 3.2% while next quarter’s revenue guidance was 3.9% above.

While some outpatient & specialty care stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 4% since the latest earnings results.

Best Q3: LifeStance Health Group NASDAQ:LFST

With over 6,600 licensed mental health professionals treating more than 880,000 patients annually, LifeStance Health (NASDAQ:LFST) provides outpatient mental health services through a network of clinicians offering psychiatric evaluations, psychological testing, and therapy across 33 states.

LifeStance Health Group reported revenues of $455.9 million, up 25.3% year on year. This print exceeded analysts’ expectations by 5.6%. Overall, it was an impressive quarter for the company with EBITDA guidance for next quarter exceeding analysts’ expectations and a beat of analysts’ EPS estimates.

“The team delivered a tremendous quarter, with execution across the business driving results that once again exceeded our expectations,” said Dave Bourdon, CEO of LifeStance. “The strong momentum gives us the confidence to further raise our full-year 2026 outlook across all financial metrics, while our positive patient outcomes, most recently across TMS and Spravato, reflect our commitment to clinical excellence. At the same time, the investments we are making in our platform, including the implementation of our new EHR, are positioning LifeStance for continued success and scale over the long term.”

LifeStance Health Group total revenue

LifeStance Health Group pulled off the biggest analyst estimate beat, fastest revenue growth, and highest full-year guidance raise in the group. Investor expectations, however, were likely higher than Wall Street’s published projections, leaving some wishing for even better results (analysts’ consensus estimates are those published by big banks and advisory firms, not the investors who make buy and sell decisions). The stock is down 9% since reporting and currently trades at $12.94.

Is now the time to buy LifeStance Health Group? Access our full analysis of the earnings results here, it’s free.

agilon health (NYSE:AGL)

Transforming how doctors care for seniors by shifting financial incentives from volume to outcomes, agilon health (NYSE:AGL) provides a platform that helps primary care physicians transition to value-based care models for Medicare patients through long-term partnerships and global capitation arrangements.

agilon health reported revenues of $1.52 billion, up 5.9% year on year, outperforming analysts’ expectations by 4.2%. The business had a very strong quarter with a beat of analysts’ EPS estimates and full-year EBITDA guidance exceeding analysts’ expectations.

agilon health total revenue

Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 7% since reporting. It currently trades at $89.54.

Is now the time to buy agilon health? Access our full analysis of the earnings results here, it’s free.

Weakest Q3: DaVita (NYSE:DVA)

With over 2,600 dialysis centers across the United States and a presence in 13 countries, DaVita (NYSE:DVA) operates a network of dialysis centers providing treatment and care for patients with chronic kidney disease and end-stage kidney disease.

DaVita reported revenues of $3.58 billion, up 4.6% year on year, exceeding analysts’ expectations by 1.7%. It was a satisfactory quarter as it also posted a beat of analysts’ EPS estimates but a slight miss of analysts’ full-year EPS guidance estimates.

DaVita delivered the slowest revenue growth among its peers. As expected, the stock is down 18.3% since the results and currently trades at $157.84.

Read our full analysis of DaVita’s results here.

U.S. Physical Therapy (NYSE:USPH)

With a nationwide footprint spanning 671 clinics across 42 states, U.S. Physical Therapy (NYSE:USPH) operates a network of outpatient physical therapy clinics and provides industrial injury prevention services to employers across the United States.

U.S. Physical Therapy reported revenues of $222.6 million, up 12.9% year on year. This number topped analysts’ expectations by 3.8%. Overall, it was a favorable quarter as it also put up a beat of analysts’ EPS estimates and full-year EBITDA guidance meeting analysts’ expectations.

The stock is up 5.9% since reporting and currently trades at $94.40.

Read our full, actionable report on U.S. Physical Therapy here, it’s free.

Encompass Health (NYSE:EHC)

With a network of 161 specialized facilities across 37 states and Puerto Rico, Encompass Health (NYSE:EHC) operates inpatient rehabilitation hospitals that help patients recover from strokes, hip fractures, and other debilitating conditions.

Encompass Health reported revenues of $1.61 billion, up 8.9% year on year. This result surpassed analysts’ expectations by 0.5%. It was a solid quarter as it also produced a solid beat of analysts’ full-year EPS guidance estimates and a beat of analysts’ EPS estimates.

Encompass Health had the weakest performance against analyst estimates and weakest full-year guidance update in the group. The stock is up 8.3% since reporting and currently trades at $132.26.

Read our full, actionable report on Encompass Health here, it’s free.

Market update

Over the past year, investors have been forced to repeatedly answer the same question: What is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership.

Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products.

By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals.

Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.